Currently, two clinical studies on c-Met CAR-T cells in the treatment of liver cancer, GC, and other solid tumors of the digestive system are being implemented in China (NCT03672305, NCT03638206) to evaluate the efficacy and safety of c-Met CAR-T cells in solid tumors of the digestive system and expect to achieve good results. Here, MET is linked to gastric cancer.